trending Market Intelligence /marketintelligence/en/news-insights/trending/3w1yN4vtPqnbW2qYhF1S_A2 content esgSubNav
In This List

Australis Capital to acquire Folium Biosciences in all-stock deal

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Australis Capital to acquire Folium Biosciences in all-stock deal

Australis Capital Inc. agreed to acquire Folium Biosciences LLC, a private manufacturer and distributor of cannabinoids, in an all-stock deal.

On completion, current members of Folium will own 89% of Australis Capital. Australis Capital, a venture capital firm that invests in cannabis and real estate, will rebrand as Folium Biosciences before the transaction.

Las Vegas-based Australis Capital plans to seek shareholder approval for the proposed transaction in the future.